Pulse Dosing Vismodegib Therapy as an Effective Treatment of Basal Cell Carcinoma: A Case Report

Main Article Content

Marisa Tandy https://orcid.org/0000-0001-6886-7477
Caroline Kruithoff https://orcid.org/0000-0003-0168-5163
Michael Noparstak


Basal Cell Carcinoma, Sonic hedgehog signaling pathway, Vismodegib


Basal cell carcinoma (BCC) is a common nonmelanoma skin cancer, frequently present on the face and head. BCC is linked to the Sonic Hedgehog (Shh) signaling pathway. Mutations within the Shh signaling pathway, involving the activation of the ligand-independent pathway by the Smoothened (Smo) protein, can lead to unregulated proliferation of basal cells, resulting in BCC. Vismodegib, a hedgehog pathway inhibitor, is a chemotherapy drug approved for targeting the Shh signaling pathway. We herein report a presentation of nodular BCC in a Caucasian female who was treated with Vismodegib. This case highlights the effectiveness of pulse dosing treatment to minimize side effects.


1. Marzuka AG, Book SE. Basal cell carcinoma: pathogenesis, epidemiology, clinical features, diagnosis, histopathology, and management. Yale J Biol Med. 2015 Jun 1;88(2):167-79. PMID: 26029015; PMCID: PMC4445438.

2. Aditya S, Rattan A. Vismodegib: A smoothened inhibitor for the treatment of advanced basal cell carcinoma. Indian Dermatol Online J. 2013 Oct;4(4):365-8. doi: 10.4103/2229-5178.120685. PMID: 24350028; PMCID: PMC3853913.

3. Nix NM, Burdine O, Walker M. Vismodegib: First-in-Class Hedgehog Pathway Inhibitor for Metastatic or Locally Advanced Basal Cell Carcinoma. J Adv Pract Oncol. 2014 Jul-Aug;5(4):294-6. doi: 10.6004/jadpro.2014.5.4.7. PMID: 26110074; PMCID: PMC4457185.

4. Li X, Sun R, Wu H, Zheng C, Long YQ. Targeting the Hedgehog pathway with novel Gli1 hydrophobic tagging degraders. Bioorg Chem. 2023 Sep;138:106649. doi: 10.1016/j.bioorg.2023.106649. Epub 2023 Jun 7. PMID: 37307715.

5. Suchors C, Kim J. Canonical Hedgehog Pathway and Noncanonical GLI Transcription Factor Activation in Cancer. Cells. 2022 Aug 14;11(16):2523. doi: 10.3390/cells11162523. PMID: 36010600; PMCID: PMC9406872.

6. Koelblinger P, Lang R. New developments in the treatment of basal cell carcinoma: update on current and emerging treatment options with a focus on vismodegib. Onco Targets Ther. 2018 Nov 23;11:8327-8340. doi: 10.2147/OTT.S135650. PMID: 30568456; PMCID: PMC6267762.

Similar Articles

1 2 3 4 5 6 > >> 

You may also start an advanced similarity search for this article.